跳至主要内容
临床试验/NCT00353431
NCT00353431已完成不适用

Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
130
试验地点
1
主要终点
Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours

研究概览

简要总结

The aim of this study is to test the safety and efficacy of a new algorithm for intensive s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose concentration ≥ 8 mmol/l)

详细描述

BACKGROUND: Prospective randomized trials have shown that near-normoglycemic blood glucose control using insulin infusions achieves a significant reduction in mortality of severely ill patients in intensive care units, of patients with acute myocardial infarction and with stroke. This implies that most severely ill patients with hyperglycemia should be treated with insulin to reach near-normoglycemia. However, this is not common practice today in emergency room admissions outside the intensive care unit, and strategies to achieve near-normoglycemia safely outside the ICU setting with s.c. injections (insulin infusions are too risky outside the ICU) have not been established.

AIM: To evaluate an insulin therapy algorithm using s.c. injections which permits effective and safe glycemic management of emergency room patients with hyperglycemia.

DESIGN: Randomized, controlled trial with an open intervention. Patients presenting with hyperglycemia on admission to the emergency room are randomized 1:1 either to conventional treatment (conventional insulin group) or to intensive treatment (intensive insulin group).

METHODS: 140 patients admitted to the medical emergency rooms of the University Hospital Basel and the Regional Hospital of Solothurn will be included and randomized as described above. All patients with plasma glucose levels exceeding 8.0 mmol/l will be included.

Exclusion criteria include severely immunocompromised patients, patients in shock, patients with terminal illnesses on palliative care, type 1 diabetes with or without ketoacidosis and patients which require intensive care unit (ICU) or cardial care unit (CCU) therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • all patients with hyperglycaemia (≥ 8.0 mmol/l) admitted to the medical emergency room.
  • patients with presumed hospitalisation in ER or medical ward of more than 48 h duration.

排除标准

  • patients in shock (defined as hypotension or shock index > 1 with oliguria, changed mental status and metabolic acidosis)
  • patients with a terminal illness on palliative care
  • patients with type 1 diabetes
  • patients with insulin pump therapy
  • patients with need for hospitalisation in the intensive or coronary care unit.
  • patients with presumed hospitalisation shorter than 48 hours
  • known pregnancy (in women with childbearing potential pregnancy test for exclusion mandatory)
  • no informed consent

研究组 & 干预措施

1

Active Comparator

Conventional insulin group:

In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.

干预措施: Novorapid ®, Novo Nordisk, Denmark (Drug)

2

Experimental

Intensive insulin therapy algorithm:

The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.

干预措施: Novorapid ®, Novo Nordisk, Denmark (Drug)

结局指标

主要结局

Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours

时间窗: 48 h

Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)

次要结局

  • Time to Reach the Target Range(24 h)
  • Frequency of Hypoglycemia(during observation of 48 hours)
  • Frequency of Severe Hypoglycaemia(during observation of 48 hours)
  • Frequency of Hypokalaemia(during observation of 48 hours)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验